Previous 10 | Next 10 |
Exelixis' (EXEL) partner Takeda Pharmaceutical (TAK) has received Japanese approval to manufacture and market Cabometyx as a treatment for patients with unresectable hepatocellular carcinoma ((HCC)) that has progressed after prior systemic therapy. Per the terms of Exelixis and Take...
— Approval based on results of two clinical trials in patients with advanced hepatocellular carcinoma who had received prior systemic therapy — Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partne...
Calithera has an important near-term catalyst that could launch the company into a significant commercialization opportunity by mid-year 2021. The company also is running a triplet therapy trial that if successful, would be the only treatment in a $10B market. Calithera is a high-...
– Presentations to be webcast on www.exelixis.com – Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following virtual investor conferences in December: Piper ...
Exelixis, Inc. (EXEL) Stifel 2020 Virtual Healthcare Conference November 18, 2020, 02:00 PM ET Company Participants Michael Morrissey - President and Chief Executive Officer Conference Call Participants Stephen Willey - Stifel Presentation Stephen Willey Good afternoon, everyone. I'm Stephen ...
BioMarin is a leader in rare disease therapy discovery with multiple competitive advantages including scale, expertise, patents and relationships. Two major catalysts for 2021 provide investors with favorable risk/reward skew afforded by a low share price that should not be ignored. ...
Exelixis, Inc. (EXEL) Credit Suisse 29th Annual Virtual Healthcare Conference November 10, 2020 16:15 ET Corporate Participants Michael Morrissey - President and Chief Executive Officer Conference Call Participants Evan Seigerman - Credit Suisse Presentation Evan Seigerman There we go. Hello,...
Image source: The Motley Fool. Exelixis Inc (NASDAQ: EXEL) Q3 2020 Earnings Call Nov 5, 2020 , 5:00 p.m. ET Operator Continue reading For further details see: Exelixis Inc (EXEL) Q3 2020 Earnings Call Transcript
Exelixis, Inc. (EXEL) Q3 2020 Earnings Conference Call November 5, 2020 5:00 PM ET Company Participants Susan Hubbard – Executive Vice President-Public Affairs and Investor Relations Mike Morrissey – President and Chief Executive Officer Chris Senner – Chief Financial Off...
Exelixis (EXEL): Q3 Non-GAAP EPS of $0.04 beats by $0.03; GAAP EPS of -$0.10 misses by $0.11.Revenue of $231.09M (-14.9% Y/Y) beats by $15.69M.“In the third quarter of 2020, the Exelixis team built the foundation to accelerate revenue growth with CABOMETYX® (cabozantinib) in ...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...